3 results
DEF 14A
APGE
Apogee Therapeutics, Inc.
24 Apr 24
Definitive proxy
4:15pm
The percentage ownership information shown in the column titled “Total Percentage Ownership” in the table below is based on 50,655,671 shares of our common stock outstanding, including 2,136,345 unvested shares of restricted common stock and 13,486,642 shares of non-voting common stock as of the date of this table (plus, as to any particular beneficial owner, any shares as to which such person has the right to acquire beneficial ownership within 60 days thereafter). The percentage ownership information shown in the column titled “Voting Power” in the table below is based on 35,032,684 shares of our voting common stock outstanding, and excludes 2,136,345 unvested shares of restricted common stock. Unless otherwise indicated, the address of each individual listed in this table is the Company’s address set forth on the first page of this Proxy Statement.
Name of Beneficial Owner | | | Number of Shares of Voting Common Stock Owned | | | Number of Shares of Non-Voting Common Stock Owned | | | Total Percentage Ownership(1) | | | Voting Power(2) | | ||||||||||||
Greater than 5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | | | |
Entities affiliated with Fairmount Funds Management LLC(3) | | | | | 2,048,647** | | | | | | 6,743,321 | | | | | | 17.4% | | | | | | 5.8%** | | |
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.(4) | | | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 16.8% | | | | | | 5.0%** | | |
Entities affiliated with FMR LLC (Fidelity)(5) | | | | | 5,018,880 | | | | | | — | | | | | | 9.9% | | | | | | 14.3% | | |
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.(6) | | | | | 2,527,901 | | | | | | — | | | | | | 5.0% | | | | | | 7.2% | | |
Entities affiliated with Deep Track Capital, LP(7) | | | | | 2,323,456 | | | | | | — | | | | | | 4.6% | | | | | | 6.6% | | |
Paragon(8) | | | | | 2,259,073 | | | | | | — | | | | | | 4.5% | | | | | | 6.4% | | |
Entities affiliated with RTW Investments, LP(9) | | | | | 2,142,592 | | | | | | — | | | | | | 4.2% | | | | | | 6.1% | | |
Entities affiliated with RA Capital(10) | | | | | 1,977,901 | | | | | | — | | | | | | 3.9% | | | | | | 5.6% | | |
Perceptive Xontogeny Venture Fund II, LP(11) | | | | | 1,977,901 | | | | | | — | | | | | | 3.9% | | | | | | 5.6% | | |
10-K
2023 FY
APGE
Apogee Therapeutics, Inc.
5 Mar 24
Annual report
6:15am
| | | | | | | | | |
| Number of | Number of | | | |||||
| | Shares of | | Shares of | | | | | |
| | Voting | | Non-Voting | | | | | |
| | Common | | Common | | Total | | | |
| | Stock | | Stock | | Percentage | | Voting | |
Name of Beneficial Owner | | Owned | | Owned | | Ownership(1) | | Power(2) | |
Greater than 5% Stockholders: | | | | | |||||
Entities affiliated with Fairmount Funds Management LLC** (3) | | 2,048,647 | ** | 6,743,321 | | 17.4 | % | 5.8 | % |
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.** (4) | | 1,750,000 | ** | 6,743,321 | | 16.8 | % | 5.0 | % |
Entities affiliated with FMR LLC (Fidelity) (5) | | 5,018,880 | | — | | 9.9 | % | 14.3 | % |
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. (6) | | 2,527,901 | | — | | 5.0 | % | 7.2 | % |
Entities affiliated with Deep Track Capital, LP (7) | | 2,323,456 | | — | | 4.6 | % | 6.6 | % |
Paragon (8) | 2,259,073 | — | 4.5 | % | 6.4 | % | |||
Entities affiliated with RTW Investments, LP (9) | 2,142,592 | — | 4.2 | % | 6.1 | % | |||
Entities affiliated with RA Capital (10) | 1,977,901 | — | 3.9 | % | 5.6 | % | |||
Perceptive Xontogeny Venture Fund II, LP (11) | 1,977,901 | — | 3.9 | % | 5.6 | % | |||
Entities affiliated with AI Biotechnology (12) | 1,940,364 | — | 3.8 | % | 5.5 | % | |||
Named Executive Officers and Directors: | | | | ||||||
Michael Henderson, M.D. (13) | 705,011 | — | 1.4 | % | 2.0 | % | |||
Carl Dambkowski, M.D. (14) | 123,123 | — | * | | * | | |||
Jane Pritchett Henderson (15) | 74,948 | — | * | | * | | |||
Mark C. McKenna (16) | 11,111 | — | * | | * | | |||
Peter Harwin (3) | 2,099,813 | 6,743,321 | 17.5 | % | 6.0 | % | |||
Jennifer Fox | — | — | * | | * | | |||
Andrew Gottesdiener, M.D. | — | — | * | | * | | |||
William (BJ) Jones, Jr. | — | — | * | | * | | |||
Tomas Kiselak (3) | 2,099,813 | 6,743,321 | 17.5 | % | 6.0 | % | |||
Nimish Shah (4) | 1,750,000 | 6,743,321 | 16.8 | % | 5.0 | % | |||
All current executive officers and directors as a group (10 persons) (17) | 6,863,819 | 20,229,963 | 53.5 | % | 19.6 | % |
- Prev
- 1
- Next